CMA says MSD operated anti-competitive Remicade scheme

The UK Competition and Markets Authority (CMA) has provisionally decided that Merck Sharp & Dohme operated an anti-competitive discount scheme for its drug Remicade (infliximab).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

MSD sues Pfizer’s Wyeth over vaccine patents

14 January 2021 Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.

Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

4 March 2019 The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

More on this story

Americas

MSD sues Pfizer’s Wyeth over vaccine patents

14 January 2021 Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.

Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

More on this story

Americas

MSD sues Pfizer’s Wyeth over vaccine patents

14 January 2021 Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.

Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour